CONCORD BIOTECH LIMITED

Concord Biotech is an R&D-based, vertically integrated biotechnology company with state-of-the-art manufacturing facilities offering fermentation and semi-synthetic APIs and finished dosage forms. Operating under cGMP practices and inspected by global regulatory agencies including the US FDA, EU-GMP, Japan's PMDA, local FDA and Korea's FDA, Concord has built more than 20 dedicated API manufacturing blocks with over 500 KL of fermentation capacity and a separate finished dosage form manufacturing unit. The company offers a diversified API portfolio spanning immunosuppressants, oncology, anti-bacterials, anti-fungals, animal health, enzymes and statins, along with contract research and manufacturing services for fermentation and semi-synthetic molecules, and is expanding its finished dosage form business starting with solid oral dosage and oral liquid immunosuppressants.